Filter posts

BIO’s Jim Greenwood Talks Pricing, Policy and Science on CSPAN

BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest …

Greenwood: A Critical Medicare Policy Has Been Delayed. Let’s Use This Opportunity to Get It Right...

In a piece for Morning Consult, BIO’s Jim Greenwood writes that while CAR-T cell therapies …

Why Concerns About a “Break Down” in Drug Pricing Are Misplaced

Just moments after it was announced the FDA had approved a new treatment for spinal …

Propelling Innovation with the Right Mix

BIO represents pioneers in the world’s most innovative industry. It’s our job to support and …

Dr. Emanuel Misses the Mark with Latest Industry Attack

Writing for The Atlantic, Dr. Ezekiel Emanuel accuses the biopharmaceutical industry of being “deceptive” when …

In 2019, Women are NOT Waiting to Climb to the Top

In celebration of International Women’s Day on March 8th, women across the globe are leading …

Two New Infographics Illustrate the Success of the Orphan Drug Act

In recognition of Rare Disease Day, BIO’s Jim Greenwood shared commentary on LinkedIn celebrating the …

Why We Need Innovation in Food and Agriculture

Two of our most beloved breakfast beverages — coffee and orange juice — are under …

Latest Measles Outbreak is a Crash Course on the Importance of Immunization

It’s hard to miss the news coming from the Pacific Northwest. Every major media outlet …

Greenwood Shines Spotlight on Insurance Industry Rip-off

Writing for The Hill, BIO’s President and CEO Jim Greenwood shined a spotlight on a …